Insider trade

Officer sold ~$127K of DXCM shares in the open market

Traded Jul 15, 2026 · Filed Jul 16, 2026

DexcomDXCM

~$127K
Reported value · 1,700 sh @ $74.42: 105K
Holds after · shares reported: +18.6%
stock since the trade · S&P 500 +1.2%, $72.73 → $86.23 on Oct 1

Why it stands out

Dexcom's Chief Legal Compliance Off sold $127K of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 15, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 16, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$126,514

Shares × reported transaction price

Timing vs results

76 days after results of Apr 30, 2026, 15 days before results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $72.73 on Jul 15, 2026, 33% above its 52-week low and 19% below its high, after a 3% drop over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $89.53 (Jul 28, 2025), 52% of the way up, from 251 adjusted closes. 30 trading days earlier: $74.87 on Jun 1, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

4 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-6.7%	-0.6%	-6.1%
30 days	+15.8%	+4.0%	+11.8%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-26-000135
Filed / recorded: Jul 16, 2026, 9:06 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Michael Jon Brown
Relationship: Officer
Officer title: EVP Chief Legal Compliance Off
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jul 15, 2026
Transaction code: S
Shares / units: 1,700
Price per share: $74.42
Acquired / disposed: Disposed (D)
Shares owned after: 104,653
Ownership form: Direct
Amendment: No

Footnotes from the filing

On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.